SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives.
8 affiliations
- 1Department of Clinical Nutrition, Gaoxian People's Hospital, Yibin, China.
- 2Department of Neurology, Gaoxian People's Hospital, Yibin, China.
- 3Department of Cardiac and Thoracic Aortic Surgery, Christian Doppler Laboratory for Mechanical Circulatory Support, Medical University of Vienna, Vienna, Austria.
- 4Department of Cardiac Surgery, Southwest Hospital of AMU, Chongqing, China.
- 5Department of Intensive Care Unit, Gaoxian People's Hospital, Yibin, China.
- 6Department of General Practice, The First Affiliated Hospital of Chengdu Medical College, Chengdu, China.
- 7Department of General Practice, Clinical Medical College, Chengdu Medical College, Chengdu, China.
- 8Department of General Practice, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Abstract
Diabetic kidney disease (DKD) is a major complication of diabetes and a leading cause of chronic kidney disease and kidney failure worldwide. Despite substantial advances in pharmacological therapy, residual risks of renal and cardiovascular disease remain considerable, underscoring the need for complementary therapeutic strategies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as cornerstone therapies for DKD because of their glucose-independent renoprotective and cardioprotective effects. Exercise, meanwhile, provides broad metabolic, cardiovascular, anti-inflammatory, and antioxidant benefits and is recommended as an integral component of diabetes and chronic kidney disease management. Increasing evidence suggests that these two interventions may exert complementary effects on several interconnected pathways involved in DKD progression, including glomerular hyperfiltration, metabolic dysregulation, oxidative stress, inflammation, mitochondrial dysfunction, and renal fibrosis. This review summarizes the pathophysiological mechanisms underlying DKD and examines the mechanistic rationale for integrating SGLT2 inhibitors with exercise. We further discuss emerging experimental and clinical evidence regarding their potential effects on renal function, metabolic control, cardiovascular health, and exercise capacity, together with important safety considerations and challenges in individualized exercise prescription. Although available evidence provides a biologically plausible basis for potentially additive interactions between these interventions, direct clinical evidence supporting the superiority of combined therapy over either intervention alone remains limited. We therefore highlight key knowledge gaps, including the lack of adequately powered randomized controlled trials, standardized exercise protocols, and validated biomarkers for monitoring treatment response. Future studies should establish the efficacy, safety, and optimal implementation of combined SGLT2 inhibitor and exercise strategies across different stages and phenotypes of DKD, thereby facilitating their translation into individualized cardiorenal care.
Related
- Exercise-based interventions for internet gaming disorder: current evidence, mechanistic rationale, and the augmenting role of serious games and digital therapeutics
- Exercise-Mediated Regulation of Ferroptosis in Diabetic Cardiomyopathy: Mechanisms and Therapeutic Perspectives
- Periostin in diabetic kidney disease: mechanistic insights, biomarkers, and therapeutic perspectives
- A Synbiotic for the Oral–Nasal Gateway: The Mechanistic Rationale, Pathogen-Targeting Profile, and Implications for Gut and Pulmonary Health
- Accelerated pacing rates to improve exercise tolerance, quality of life, and arrhythmia burden in patients with evidence of heart failure with preserved ejection fraction: The PACE-UP rationale and design
BibTeX
@article{li2026sglt2,
title = {{SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives.}},
author = {Huajuan Li and Min Ai and Xiangyu He and Caijun Liu and Xuegui Ju},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1968588},
url = {https://europepmc.org/article/MED/42923500},
note = {CC BY},
}
RIS
TY - JOUR
TI - SGLT2 inhibitors and exercise in diabetic kidney disease: mechanistic rationale, emerging clinical evidence, and future perspectives.
AU - Huajuan Li
AU - Min Ai
AU - Xiangyu He
AU - Caijun Liu
AU - Xuegui Ju
PY - 2026
DA - 2026/10/08
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1968588
UR - https://europepmc.org/article/MED/42923500
AB - Diabetic kidney disease (DKD) is a major complication of diabetes and a leading cause of chronic kidney disease and kidney failure worldwide. Despite substantial advances in pharmacological therapy, residual risks of renal and cardiovascular disease remain considerable, underscoring the need for complementary therapeutic strategies. Sodium-glucose cotransporter 2 (SGLT2) inhibitors have emerged as cornerstone therapies for DKD because of their glucose-independent renoprotective and cardioprotective effects. Exercise, meanwhile, provides broad metabolic, cardiovascular, anti-inflammatory, and antioxidant benefits and is recommended as an integral component of diabetes and chronic kidney disease management. Increasing evidence suggests that these two interventions may exert complementary effects on several interconnected pathways involved in DKD progression, including glomerular hyperfiltration, metabolic dysregulation, oxidative stress, inflammation, mitochondrial dysfunction, and renal fibrosis. This review summarizes the pathophysiological mechanisms underlying DKD and examines the mechanistic rationale for integrating SGLT2 inhibitors with exercise. We further discuss emerging experimental and clinical evidence regarding their potential effects on renal function, metabolic control, cardiovascular health, and exercise capacity, together with important safety considerations and challenges in individualized exercise prescription. Although available evidence provides a biologically plausible basis for potentially additive interactions between these interventions, direct clinical evidence supporting the superiority of combined therapy over either intervention alone remains limited. We therefore highlight key knowledge gaps, including the lack of adequately powered randomized controlled trials, standardized exercise protocols, and validated biomarkers for monitoring treatment response. Future studies should establish the efficacy, safety, and optimal implementation of combined SGLT2 inhibitor and exercise strategies across different stages and phenotypes of DKD, thereby facilitating their translation into individualized cardiorenal care.
SN - 2296-858X
ER -